Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection.
10.1016/j.apsb.2024.08.009
- Author:
Chunhua MA
1
;
Junbiao CHANG
1
;
Bin YU
2
Author Information
1. State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, 453007, China.
2. College of Chemistry, Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Zhengzhou University, Zhengzhou 450001, China.
- Publication Type:Journal Article
- Keywords:
Antiretroviral medication;
Capsid inhibitor;
HIV prevention;
HIV-1 infection;
Lenacapavir;
Multidrug resistance
- From:
Acta Pharmaceutica Sinica B
2024;14(12):5512-5514
- CountryChina
- Language:English
